These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33187552)

  • 1. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells.
    Ciocan-Cartita CA; Jurj A; Zanoaga O; Cojocneanu R; Pop LA; Moldovan A; Moldovan C; Zimta AA; Raduly L; Pop-Bica C; Buse M; Budisan L; Virag P; Irimie A; Gomes Dias SM; Berindan-Neagoe I; Braicu C
    J Exp Clin Cancer Res; 2020 Nov; 39(1):241. PubMed ID: 33187552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
    Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
    Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
    Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
    PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer.
    Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H
    J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer.
    Zhuang F; Huang S; Liu L
    Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
    Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
    Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast Cancer by Single-Cell Transcriptomic Analysis.
    Foutadakis S; Kordias D; Vatsellas G; Magklara A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
    Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
    Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
    Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
    Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein.
    Abd-Ellatef GEF; Gazzano E; El-Desoky AH; Hamed AR; Kopecka J; Belisario DC; Costamagna C; S Marie MA; Fahmy SR; Abdel-Hamid AZ; Riganti C
    Pharmacol Res; 2022 Jan; 175():105975. PubMed ID: 34785319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative transcriptome analysis of triple negative breast cancer profiles for identification of druggable targets.
    Arumugam P; Ramesh V; Sampathkumar B; Perumalsamy H; Balusamy SR; Suganya K; Balraj S; Nachimuthu SK; Sundaravadivelu S
    J Biomol Struct Dyn; 2023; 41(21):12106-12119. PubMed ID: 36617953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
    Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
    Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M
    Liu X; Li P; Huang Y; Li H; Liu X; Du Y; Lin X; Chen D; Liu H; Zhou Y
    Redox Biol; 2024 Feb; 69():102993. PubMed ID: 38104484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
    Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
    Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
    BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.